Yoh Hidaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yoh Hidaka has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Yoshinori Iwatani
Department of Biomedical Informatics, Division of Health Sciences, Osaka University Graduate School of Medicine, Yamadaoka 1-7, Suita, Osaka 565-0871, Japan
9 shared publications Keiko Takeoka
4 shared publications- Mikio Watanabe
Center for Twin Research, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan
4 shared publications - Nobuyuki Amino
Department of Laboratory Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
4 shared publications - Toru Takano
Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
4 shared publications - Hiroyuki Hanada
Division of Laboratory for Clinical Investigation, Department of Medical Technology Osaka University Hospital, Suita, Japan
2 shared publications
Latest Publications
- 1 April 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (4) , 519-530
Effects of Levothyroxine Treatment on Fertility and Pregnancy Outcomes in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Subclinical hypothyroidism, elevated thyroid-stimulating hormone (TSH) and normal free thyroxine (FT4) levels, is associated with multiple adverse pregnancy outcomes. Despite the uncertainty regarding the effectiveness of levothyroxine treatment on pregnancy outcomes in subclinical hypothyroidism, levothyroxine is widely administered with a threshold TSH level of 2.5 mU/L. The aim of this study is to investigate the efficacy of periconceptional levothyroxine treatment for subclinical hypothyroidism, including TSH levels >2.5 mU/L, and identify the characteristics of subclinical hypothyroidism that can benefit from levothyroxine treatment. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials from inception to February 2023. We analyzed the pooled effects of levothyroxine on subclinical hypothyroidism before and during pregnancy. The main outcomes before pregnancy were live birth, pregnancy, and miscarriage. The main outcomes during pregnancy were live birth, miscarriage, and preterm birth. We conducted subgroup analyses to compare the effects of levothyroxine on subclinical hypothyroidism with TSH levels of 2.5–4.0 mU/L and >4.0 mU/L. Results: Of the 795 studies identified, 25 full-text articles were screened for eligibility. Finally, five studies on pre-conception treatment with 763 participants and seven studies on treatment during early pregnancy with 2,504 participants were analyzed. Pre-conception levothyroxine treatment showed no effect in improving live births and pregnancies, or decreasing miscarriages (risk ratio (RR):1.41; 95% confidence interval (CI):0.84–2.36, RR:1.73; 95%CI:0.88–3.39, and RR:0.46; 95%CI:0.11–2.00, respectively). Levothyroxine treatment during pregnancy showed no effect in improving live births (RR:1.03; 95%CI:0.98–1.09) or decreasing miscarriage rates (RR:0.99; 95%CI:0.65–1.51). The effect of levothyroxine treatment on preterm birth during pregnancy was significantly different depending on the TSH values (p=0.04); a positive effect was shown in the subclinical hypothyroidism subgroup with TSH >4.0 mU/L (RR:0.47; 95%CI:0.20–1.10), while no effect was shown in the subgroup with TSH 2.5-4.0 mU/L (RR:1.35; 95%CI:0.79–2.31). Conclusions: Pre-conceptional levothyroxine treatment does not improve fertility or decrease the incidence of miscarriages. However, further well-designed studies are needed for pre-conceptional treatment, especially in TSH >4.0 mU/L. Levothyroxine treatment during pregnancy had a positive effect on preterm birth; nevertheless, this was only applicable to subclinical hypothyroidism with TSH >4.0 mU/L.
- 1 April 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (4) , 519-530
Effects of Levothyroxine Treatment on Fertility and Pregnancy Outcomes in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Subclinical hypothyroidism, elevated thyroid-stimulating hormone (TSH) and normal free thyroxine (FT4) levels, is associated with multiple adverse pregnancy outcomes. Despite the uncertainty regarding the effectiveness of levothyroxine treatment on pregnancy outcomes in subclinical hypothyroidism, levothyroxine is widely administered with a threshold TSH level of 2.5 mU/L. The aim of this study is to investigate the efficacy of periconceptional levothyroxine treatment for subclinical hypothyroidism, including TSH levels >2.5 mU/L, and identify the characteristics of subclinical hypothyroidism that can benefit from levothyroxine treatment. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials from inception to February 2023. We analyzed the pooled effects of levothyroxine on subclinical hypothyroidism before and during pregnancy. The main outcomes before pregnancy were live birth, pregnancy, and miscarriage. The main outcomes during pregnancy were live birth, miscarriage, and preterm birth. We conducted subgroup analyses to compare the effects of levothyroxine on subclinical hypothyroidism with TSH levels of 2.5–4.0 mU/L and >4.0 mU/L. Results: Of the 795 studies identified, 25 full-text articles were screened for eligibility. Finally, five studies on pre-conception treatment with 763 participants and seven studies on treatment during early pregnancy with 2,504 participants were analyzed. Pre-conception levothyroxine treatment showed no effect in improving live births and pregnancies, or decreasing miscarriages (risk ratio (RR):1.41; 95% confidence interval (CI):0.84–2.36, RR:1.73; 95%CI:0.88–3.39, and RR:0.46; 95%CI:0.11–2.00, respectively). Levothyroxine treatment during pregnancy showed no effect in improving live births (RR:1.03; 95%CI:0.98–1.09) or decreasing miscarriage rates (RR:0.99; 95%CI:0.65–1.51). The effect of levothyroxine treatment on preterm birth during pregnancy was significantly different depending on the TSH values (p=0.04); a positive effect was shown in the subclinical hypothyroidism subgroup with TSH >4.0 mU/L (RR:0.47; 95%CI:0.20–1.10), while no effect was shown in the subgroup with TSH 2.5-4.0 mU/L (RR:1.35; 95%CI:0.79–2.31). Conclusions: Pre-conceptional levothyroxine treatment does not improve fertility or decrease the incidence of miscarriages. However, further well-designed studies are needed for pre-conceptional treatment, especially in TSH >4.0 mU/L. Levothyroxine treatment during pregnancy had a positive effect on preterm birth; nevertheless, this was only applicable to subclinical hypothyroidism with TSH >4.0 mU/L.
- 1 September 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (9) , 1295-1299
10-Year survey on serum antibody positivity rates and titers for measles and rubella in healthcare workers; an observational study at a Japanese university hospital
- 1 September 2021
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 27 (9) , 1295-1299
10-Year survey on serum antibody positivity rates and titers for measles and rubella in healthcare workers; an observational study at a Japanese university hospital
- 1 October 2012
- Vol. 60 (10) , 932-54
[Report of immunoassay control surveys conducted in the past 30 years by the Subcommittee for Radioisotope in vitro Test, the Medical Science and Pharmaceutical Committee, and the Japan Radioisotope Association].
Immunoassay control surveys, were conducted by the Subcommittee for Radioisotope in vitro Test, the Medical Science and Pharmaceutical Committee, and the Japan Radioisotope Association, between 1978 to 2008. A total of 40 analytes for 26 hormones, 14 tumor markers and pharmaceutical drugs were investigated in participating facilities. In the first immunoassay control survey in 1978, samples were measured using only RI kits, however, non-RI kits increased gradually during the next 30 years. In the 30th immunoassay control survey, more than 90% samples were measured using non-RI kits. Coefficient variation (CV) of intra-kits has been decreasing yearly in all analytes for hormones as well as tumor markers. However, improvement of CV in inter-kits has not been seen in the past 30 years by a lack of international standards, although there has been continuous effort over the years for the standardization of immunoassay. Growth hormone (GH) deficiency has been diagnosed using various loading tests. However, the clinical diagnosis varies according to the GH kit used. Standardization for GH measurement has been possible by using recombinant GH as the standard among commercial GH kits. The diagnosis of subclinical Cushing's syndrome also varies according to the cortisol kits being used. Candidate reference measurement procedure and low level cortisol standards have been developed by the Biomedical Standard Section, of the National Metrology Institute of Japan. Standardization of measurement is necessary for improvement of immunoassay.
- 1 October 2012
- Vol. 60 (10) , 932-54
[Report of immunoassay control surveys conducted in the past 30 years by the Subcommittee for Radioisotope in vitro Test, the Medical Science and Pharmaceutical Committee, and the Japan Radioisotope Association].
Immunoassay control surveys, were conducted by the Subcommittee for Radioisotope in vitro Test, the Medical Science and Pharmaceutical Committee, and the Japan Radioisotope Association, between 1978 to 2008. A total of 40 analytes for 26 hormones, 14 tumor markers and pharmaceutical drugs were investigated in participating facilities. In the first immunoassay control survey in 1978, samples were measured using only RI kits, however, non-RI kits increased gradually during the next 30 years. In the 30th immunoassay control survey, more than 90% samples were measured using non-RI kits. Coefficient variation (CV) of intra-kits has been decreasing yearly in all analytes for hormones as well as tumor markers. However, improvement of CV in inter-kits has not been seen in the past 30 years by a lack of international standards, although there has been continuous effort over the years for the standardization of immunoassay. Growth hormone (GH) deficiency has been diagnosed using various loading tests. However, the clinical diagnosis varies according to the GH kit used. Standardization for GH measurement has been possible by using recombinant GH as the standard among commercial GH kits. The diagnosis of subclinical Cushing's syndrome also varies according to the cortisol kits being used. Candidate reference measurement procedure and low level cortisol standards have been developed by the Biomedical Standard Section, of the National Metrology Institute of Japan. Standardization of measurement is necessary for improvement of immunoassay.
- 1 August 2012
- Vol. 60 (8) , 748-52
[FACS-mQ as a powerful clinical test in the cancer stem cell era].
Stem cells are pluripotent and self renewing, and possess an ability to differentiate into the various cell types of a particular tissue. In cancer tissues, existence of cells showing biological similarities with stem cells, named cancer stem cells (CSC), are known to regulate the growth of the tissue and determine its prognosis. Stem cells and CSCs usually exist as minor populations of cells in a tissue. Detection and analysis of these cells are usually laborious even using fluorescence activated cell sorting (FACS) with the conventional protocols. Considering these drawbacks, we developed a novel analytical method named mRNA quantification after FACS (FACS-mQ). In FACS-mQ, cells are labeled with a fluorescent dye in a manner that minimizes RNA degradation, then cells sorted by FACS are examined by analyzing their gene expression profile. We established protocols to obtain single cells from clinical samples for flow cytometry analysis. Further, we performed FACS-mQ analysis using fluorescence-labeled antibodies, cRNA probes and locked nucleic acid (LNA) probes. Evident decrease of intracellular RNAs did not observed in FACS-mQ using immunocytochemistry. Approximately 60% of intracellular RNA was preserved after in situ hybridization using cRNA probes. These RNAs from a small number of sorted cells were suitable for quantitative analysis to establish gene expression profiles. FACS-mQ does not require laborious and time-consuming procedures; thus, it is expected to facilitate research on stem cells or cancer stem cells.
- 1 August 2012
- Vol. 60 (8) , 748-52
[FACS-mQ as a powerful clinical test in the cancer stem cell era].
Stem cells are pluripotent and self renewing, and possess an ability to differentiate into the various cell types of a particular tissue. In cancer tissues, existence of cells showing biological similarities with stem cells, named cancer stem cells (CSC), are known to regulate the growth of the tissue and determine its prognosis. Stem cells and CSCs usually exist as minor populations of cells in a tissue. Detection and analysis of these cells are usually laborious even using fluorescence activated cell sorting (FACS) with the conventional protocols. Considering these drawbacks, we developed a novel analytical method named mRNA quantification after FACS (FACS-mQ). In FACS-mQ, cells are labeled with a fluorescent dye in a manner that minimizes RNA degradation, then cells sorted by FACS are examined by analyzing their gene expression profile. We established protocols to obtain single cells from clinical samples for flow cytometry analysis. Further, we performed FACS-mQ analysis using fluorescence-labeled antibodies, cRNA probes and locked nucleic acid (LNA) probes. Evident decrease of intracellular RNAs did not observed in FACS-mQ using immunocytochemistry. Approximately 60% of intracellular RNA was preserved after in situ hybridization using cRNA probes. These RNAs from a small number of sorted cells were suitable for quantitative analysis to establish gene expression profiles. FACS-mQ does not require laborious and time-consuming procedures; thus, it is expected to facilitate research on stem cells or cancer stem cells.
- 19 January 2011
- Published by Springer Nature in Molecular Biotechnology
- Vol. 49 (1) , 42-47
mRNA Quantification After Fluorescence Activated Cell Sorting Using Locked Nucleic Acid Probes
Recently, we have established an in-tube in situ hybridization method named mRNA quantification after fluorescence activated cell sorting (FACS-mQ), in which a specific RNA in a particular cell type is stained with a florescent dye, allowing the stained cells to be selected by FACS without suffering excessive RNA degradation. Using this method, the biological characteristics of the sorted cells can be determined by analyzing their gene expression profile. In this study, we used locked nucleic acid (LNA) oligonucleotides, which are known to enhance both the sensitivity and specificity of RNA detection, as hybridization probes in FACS-mQ. When we used a LNA probe targeting the human 28S sequence, we were able to efficiently separate human cells from rat cells. Using LNA probes, the hybridization step was shortened to 1 h. After the hybridization step, 84.6% RNA was preserved; thus, we were able to successfully measure gene expression levels in each type of cell after FACS. Providing the LNA probe efficiently hybridizes with the target sequence, FACS-mQ with an LNA probe is a powerful tool for separating particular cells and determining their biological characteristics by analyzing their gene expression profile.
- 19 January 2011
- Published by Springer Nature in Molecular Biotechnology
- Vol. 49 (1) , 42-47
mRNA Quantification After Fluorescence Activated Cell Sorting Using Locked Nucleic Acid Probes
Recently, we have established an in-tube in situ hybridization method named mRNA quantification after fluorescence activated cell sorting (FACS-mQ), in which a specific RNA in a particular cell type is stained with a florescent dye, allowing the stained cells to be selected by FACS without suffering excessive RNA degradation. Using this method, the biological characteristics of the sorted cells can be determined by analyzing their gene expression profile. In this study, we used locked nucleic acid (LNA) oligonucleotides, which are known to enhance both the sensitivity and specificity of RNA detection, as hybridization probes in FACS-mQ. When we used a LNA probe targeting the human 28S sequence, we were able to efficiently separate human cells from rat cells. Using LNA probes, the hybridization step was shortened to 1 h. After the hybridization step, 84.6% RNA was preserved; thus, we were able to successfully measure gene expression levels in each type of cell after FACS. Providing the LNA probe efficiently hybridizes with the target sequence, FACS-mQ with an LNA probe is a powerful tool for separating particular cells and determining their biological characteristics by analyzing their gene expression profile.
- 1 November 2009
- Vol. 57 (11) , 1058-63
[Clinical significance of apolipoprotein B-48 (apoB-48) in patients with thyroid disease].
Apolipoprotein B-48 (apoB-48) is a constituent of chylomicrons and chylomicron remnants, and its serum concentration is thought to be one of the risk factors for atherosclerosis. Clinically overt hypothyroidism (OH) has been associated with accelerated and premature coronary atherosclerosis. In the current study, we measured the serum apoB-48 concentration in patients with hyperthyroidism and hypothyroidism. We also evaluated the correlations between serum apoB-48 and thyroid hormones, from which a clinical significance of apoB-48 measurement in thyroid disease was deduced. Serum apoB-48 concentration was measured by chemiluminescence enzyme immunoassay (CLEIA) and it correlated with thyroid stimulating hormone (TSH), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and triglycerides(TG), but negatively correlated with free thyroxine (FT4) and free triiodothyronine (FT3). In a cross-sectional study, serum apoB-48 concentrations were significantly higher in OH subjects (8.4 +/- 5.4 microg/ml) compared to those in 70 hyperthyroid subjects (5.0 +/- 3.9 microg/ml) and 50 normal subjects (6.3 +/- 4.9 microg/ml). After L-T4 replacement, serum apoB-48 concentrations were decreased in OH patients. However, these changes were smaller compared to those of TSH, FT4 and FT3. Serum apoB-48 levels and thyroid hormones and lipid profiles were measured in 31 SH patients and 34 normal subjects. Significant difference was noted in serum apoB-48, TG and TSH between patients with SH and normal. In conclusion, serum apoB-48 concentration depends on thyroid status like TC, LDL-C and TG. Thyroid hormone replacement therapy may reduce serum apoB-48 concentrations in patients with OH. Therefore, increased serum apoB-48 concentrations may contribute to the increased risk of atherosclerosis and premature coronary artery disease in the hypothyroid state.
- 1 November 2009
- Vol. 57 (11) , 1058-63
[Clinical significance of apolipoprotein B-48 (apoB-48) in patients with thyroid disease].
Apolipoprotein B-48 (apoB-48) is a constituent of chylomicrons and chylomicron remnants, and its serum concentration is thought to be one of the risk factors for atherosclerosis. Clinically overt hypothyroidism (OH) has been associated with accelerated and premature coronary atherosclerosis. In the current study, we measured the serum apoB-48 concentration in patients with hyperthyroidism and hypothyroidism. We also evaluated the correlations between serum apoB-48 and thyroid hormones, from which a clinical significance of apoB-48 measurement in thyroid disease was deduced. Serum apoB-48 concentration was measured by chemiluminescence enzyme immunoassay (CLEIA) and it correlated with thyroid stimulating hormone (TSH), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and triglycerides(TG), but negatively correlated with free thyroxine (FT4) and free triiodothyronine (FT3). In a cross-sectional study, serum apoB-48 concentrations were significantly higher in OH subjects (8.4 +/- 5.4 microg/ml) compared to those in 70 hyperthyroid subjects (5.0 +/- 3.9 microg/ml) and 50 normal subjects (6.3 +/- 4.9 microg/ml). After L-T4 replacement, serum apoB-48 concentrations were decreased in OH patients. However, these changes were smaller compared to those of TSH, FT4 and FT3. Serum apoB-48 levels and thyroid hormones and lipid profiles were measured in 31 SH patients and 34 normal subjects. Significant difference was noted in serum apoB-48, TG and TSH between patients with SH and normal. In conclusion, serum apoB-48 concentration depends on thyroid status like TC, LDL-C and TG. Thyroid hormone replacement therapy may reduce serum apoB-48 concentrations in patients with OH. Therefore, increased serum apoB-48 concentrations may contribute to the increased risk of atherosclerosis and premature coronary artery disease in the hypothyroid state.
- 1 January 2009
- Vol. 57 (1) , 17-23
[Analysis of the causal relations between serum ferritin elevation and latent pathologic factors by structural equation modeling].
Serum ferritin increases in various disorders and clinical conditions such as iron overload, tissue disorders, and inflammation. However causal associations between the serum ferritin level and clinical factors that influence serum ferritin level or between these factors are not well characterized. We analyzed the ferritin level and other laboratory data including transferrin saturation (TF%), enzyme activities, and inflammatory protein levels in the sera of 124 patients with hyperferritinemia. We identified latent pathologic factors representing cell damage and inflammatory status and assumed causal relations between serum ferritin elevation and these factors. Structural equation modeling was used to verify causal relations and the adequacy of latent factors. A model that quantitatively explained serum ferritin elevation was identified. The direct effect of the cell damage factor on serum ferritin indicated cell destruction and decreased ferritin clearance. In contrast, the inflammation factor directly increased the ferritin level, but indirectly decreased it via TF%. These causal relations may quantitatively explain the mechanism of serum ferritin levels in patients with hyperferritinemia.
- 1 January 2009
- Vol. 57 (1) , 17-23
[Analysis of the causal relations between serum ferritin elevation and latent pathologic factors by structural equation modeling].
Serum ferritin increases in various disorders and clinical conditions such as iron overload, tissue disorders, and inflammation. However causal associations between the serum ferritin level and clinical factors that influence serum ferritin level or between these factors are not well characterized. We analyzed the ferritin level and other laboratory data including transferrin saturation (TF%), enzyme activities, and inflammatory protein levels in the sera of 124 patients with hyperferritinemia. We identified latent pathologic factors representing cell damage and inflammatory status and assumed causal relations between serum ferritin elevation and these factors. Structural equation modeling was used to verify causal relations and the adequacy of latent factors. A model that quantitatively explained serum ferritin elevation was identified. The direct effect of the cell damage factor on serum ferritin indicated cell destruction and decreased ferritin clearance. In contrast, the inflammation factor directly increased the ferritin level, but indirectly decreased it via TF%. These causal relations may quantitatively explain the mechanism of serum ferritin levels in patients with hyperferritinemia.